Clinical Trial Update: Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) [Phase 1, Phase 2]

View source ↗

Summary

Extension study evaluating nilotinib in adults with imatinib-resistant/intolerant CML or relapse/refractory Philadelphia-positive ALL; completed Phase 1/2 trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED